Summary of cell epitopes on mMSCs and human MSCs
. | B1/6 . | FVB/N . | BALB/c . | DBA1 . | Human MSCs14 . |
|---|---|---|---|---|---|
| Hematopoietic markers | |||||
| CD11b | - | - | - | - | - |
| CD34 | +++ | ++ | + | + | - |
| CD45 | - | - | - | - | - |
| Sca-1 (ly-6A/E) | +++ | +++ | - | + | NA |
| CD106 (VCAM-1) | ++ | ++ | + | + | ++ |
| Endothelial markers | |||||
| Flk1 (VEGF-R2) | - | - | - | - | ++ |
| CD31 (PECAM) | - | - | - | - | - |
| CD90 (Thy1)* | - | - | - | - | +++ |
| CD117 (C-kit) | - | - | - | - | - |
| Lineage panel (CD11b, Ter-119, CD45R/B220, Ly-6G and Ly-6C, CD3e) | - | - | - | - | NA |
. | B1/6 . | FVB/N . | BALB/c . | DBA1 . | Human MSCs14 . |
|---|---|---|---|---|---|
| Hematopoietic markers | |||||
| CD11b | - | - | - | - | - |
| CD34 | +++ | ++ | + | + | - |
| CD45 | - | - | - | - | - |
| Sca-1 (ly-6A/E) | +++ | +++ | - | + | NA |
| CD106 (VCAM-1) | ++ | ++ | + | + | ++ |
| Endothelial markers | |||||
| Flk1 (VEGF-R2) | - | - | - | - | ++ |
| CD31 (PECAM) | - | - | - | - | - |
| CD90 (Thy1)* | - | - | - | - | +++ |
| CD117 (C-kit) | - | - | - | - | - |
| Lineage panel (CD11b, Ter-119, CD45R/B220, Ly-6G and Ly-6C, CD3e) | - | - | - | - | NA |
mMSCs were analyzed by FACS, as in Figure 6. Each antibody was tested individually, and isotype controls were gated to less than 1%. Samples were scored as - if less than 2% of the cells were positive, + if more than 2% and less than 20% were positive, ++ if more than 20% and less than 75% were positive, and +++ if more than 75% were positive. NA indicates not available.
For B1/6, antibody CD90.2 (Thy1.2) was used. For all other strains, antibody CD90.1 (Thy1.1) was used.